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The article by Burdett et al.1 published in this issue of the Journal of Thoracic Oncologyis a systematic review and meta-analysis of randomized clinical trials (RCTs) designed
to compare the combination of induction chemotherapy followed by surgical resection
with surgical resection alone for locally advanced non-small cell lung cancer (NSCLC),
mainly stage IIIa. They identified 12 RCTs and could combine data from seven of them
including a total of 988 patients (75% of eligible patients). Their conclusion is that
induction chemotherapy followed by lung resection has a significant benefit compared
with resection alone. Their results confirm those of the first positive RCTs, published in
1994,2,3 that brought much hope to patients with locally advanced NSCLC and, although
based on a small number of patients, triggered a change in clinical practice all over the
world. Patients who would have otherwise been excluded from surgical treatment because
of mediastinal nodal involvement had the chance to undergo lung resection after chemo-
therapy. It was also evident that accurate clinical staging was of paramount importance
before starting induction chemotherapy, and techniques providing tissue diagnosis (high-
est clinical classification certainty; certainty factor C3)4 of the anatomical extension of the
tumor became mandatory in most clinical trial protocols. This was necessary because if
induction therapy is initiated with no cytology or tissue evidence of the anatomical
extension of the tumor, the clinical tumor stage will never be known; consequently, the
apparent tumor response and downstaging will not be reliable.
These RCTs were designed to test whether induction chemotherapy added to lung
resection had any advantage over resection alone. Now we know the answer is that
induction chemotherapy has some benefit. However, the role of surgical resection in
locally advanced NSCLC remained unclear. Two recent RCTs, one from North America5
and one from Europe,6 have shown that lung resection after either induction chemotherapy
or concurrent induction chemotherapy and radiotherapy does not add any significant
survival benefit in the overall population of patients with cytological or histological
proven clinical N2 disease. The results of these two RCTs confirmed what had been
observed in several phase II and phase III clinical trials: those patients whose tumors
underwent pathologic downstage after induction treatment (from cN2 to ypN0; “y”
indicates tumor classification after induction treatment, both clinical [yc] and pathologic
[yp]) and were completely resected had a much higher probability of long-term survival
compared with those whose tumors were not downstaged or incompletely resected.
Apparently, this subgroup of patients is the one that would benefit from lung resection
after induction treatment; the one for whom it would be worth taking the risk of increased
postoperative morbidity and mortality; the one that would have to be clearly identified
after induction before indicating lung resection. This means that restaging, especially
invasive restaging to provide cytological or histological evidence of downstaging, after
induction has to be taken very seriously.7 Invasive restaging is a challenge for the surgeon.
Although it can be done with endoscopic techniques and fine-needle aspiration (FNA),8
they are not generalized enough for routine clinical practice. Remediastinoscopy is
performed routinely in some institutions,9–12 and its results are better than those obtained
by computed tomography scan or positron emission tomography scan. Suboptimal
experience with mediastinoscopy and intrinsic difficulties related to peritracheal adhesions
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will prevent remediastinoscopy from being a universal restag-
ing procedure. The more frequent use of endoscopic tech-
niques with FNA would decrease the need for staging medi-
astinoscopies, and this procedure could be reserved for
restaging.
Progress in medical knowledge is slow, and answers
usually lead to new questions. We now know that induction
therapy followed by lung resection has an increased survival
benefit compared with resection alone. We also know that
surgical resection after induction chemotherapy or chemora-
diotherapy has some survival benefit in the selected popula-
tion of patients with cN2 NSCLC whose tumors underwent
downstaging to ypN0. We know how important it is to
identify these patients preoperatively. However, we do not
yet know whether these patients with downstaged tumors
after induction would have a similar survival without surgical
treatment, with more non-surgical treatment, or with no
additional treatment at all after induction. To answer these
questions we need a new RCT. In this trial, cN2 NSCLC
should have cytological or histological confirmation; restag-
ing should provide cytological or histological evidence of
tumor response and downstaging, obtained either by endo-
scopic techniques and FNA or with minimally invasive sur-
gical procedures (mediastinoscopy or remediastinoscopy,
parasternal mediastinotomy, thoracoscopy); then, those pa-
tients whose tumors underwent downstaging to ycN0 should
be randomized to lung resection and non-surgical treatment
or follow-up with no additional treatment. This RCT will not
be easy to conduct. We know the theory, but, in practice,
there is too much heterogeneity in clinical staging, and
highest certainty restaging is just beginning to be considered.
It is our responsibility to try to answer these important
questions, but recruiting patients for RCTs is difficult. The 12
RCTs identified by Burdett et al.1 included 1310 patients and
were conducted over a period of 20 years, from 1985 to 2004.
Assuming, roughly, that in this period of time at least 20
million persons in the whole world had the disease, and that
approximately one third of them, or more than 6.6 million,
had mediastinal nodal involvement, the number of patients
included in RCTs is very low.
At the moment, in clinical practice, until we have solid
answers to the question of the ideal treatment for N2 NSCLC,
the responsibility of the thoracic surgeon, as member of the
multidisciplinary team treating patients with lung cancer, is to
stage and restage tumors with the highest clinical certainty, to
provide tissue evidence of downstaging, and to ensure that
the resection planed will be complete. So far, these are the
only parameters associated with prolonged survival.
REFERENCES
1. Burdett S, Stewart L, Rydzewska L. A systematic review and meta-
analysis of the literature: chemotherapy and surgery versus surgery alone
in non-small cell lung cancer. J Thorac Oncol 2006;1:XX–XX.
2. Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial com-
paring preoperative chemotherapy plus surgery with surgery alone in
patients with non-small-cell lung cancer. N Engl J Med 1994;330:153–
158.
3. Roth JA, Fosella F, Komaki R, et al. A randomized trial comparing
perioperative chemotherapy and surgery with surgery alone in resectable
stage IIIa non-small cell lung cancer. J Nat Cancer Inst 1994;86:673–
680.
4. Sobin LH, Wittekind CH,. International Union Against Cancer (UICC)
TNM classification of malignant tumors, 6th edition, New York: Wiley-
Liss, 2002. Pp. 15.
5. Albain KS, Swann RS, Rusch VR, et al. Phase III study of concurrent
chemotherapy and radiotherapy (CT/RT) versus CT/RT followed by
surgical resection for stage IIIA-N2 non-small cell lung cancer: out-
comes update of North American Intergroup 0139 (RTOG 9309) (Ab-
stract). J Clin Oncol 2005;23:624s.
6. Van Meerbeeck J, Kramer G, Van Schil PE, et al. A randomized trial of
radical surgery versus thoracic radiotherapy in patients with stage
IIIA-N2 non-small cell lung cancer after response to induction chemo-
therapy (EORTC 08941) (Abstract). J Clin Oncol 2005;23:1095s.
7. Rami-Porta R. Restaging after induction therapy for non-small cell lung
cancer. Ann Thorac Cardiovasc Surg 2002;8:325–327.
8. Van Schil P. The restaging issue. Lung Cancer 2003;42(Suppl 1):s39–
s45.
9. Mateu-Navarro M, Rami-Porta R, Bastus-Piulats R, Cirera-Noguera L,
Gonza´lez-Pont G. Remediastinoscopy after induction chemotherapy in
non-small cell lung cancer. Ann Thorac Surg 2000;70:391–395.
10. Rami-Porta R, Mateu-Navarro M, Serra-Mitjans M, Herna´ndez-Rodrı´-
guez H. Remediastinoscopy: comments and updated results. Lung Can-
cer 2003;42:363–364.
11. Van Schil P, Van Der Schoot J, Poniewierski J, et al. Remediastinoscopy
after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer
2002;37:281–285.
12. Stamatis G, Fechner S, Hillejan L, et al. Repeat mediastinoscopy as a
restaging procedure. Pneumologie 2005;59:862–866.
Rami–Porta Journal of Thoracic Oncology • Volume 1, Number 7, September 2006
Copyright © 2006 by the International Association for the Study of Lung Cancer606
